Emami Limited has informed the Exchange regarding a press release dated May 21, 2026, titled "Emami Reports Q4FY26 Results; Core Domestic Portfolio Remains Resilient Amid External Headwinds".
EMAMILTD · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 3.8 pts less than Nifty Smallcap 250 and 2.7 pts less than its Personal Care peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Emami reported Q4FY26 consolidated revenues of ₹925 crore, down 4% YoY, impacted by an unfavorable summer season and geopolitical disruptions in West Asia. Despite this, the non-summer domestic portfolio delivered healthy 11% growth, demonstrating underlying business resilience. EBITDA declined 15% to ₹187 crore due to increased A&P investments (+12%), though gross margins expanded by 250 bps to 68.4%. PAT stood at ₹143 crore, down 11.7%. For FY26, revenues were ₹3,780 crore, EBITDA ₹964 crore, and PAT ₹775 crore. The company made strategic investments, including making Axiom Ayurveda (AloFrut) a subsidiary and acquiring a majority stake in IncNut (Vedix, SkinKraft) to strengthen its presence in wellness and personalised beauty segments.
The quarter showed temporary headwinds impacting near-term performance, but strong margin expansion and portfolio diversification indicate resilience. The company remains debt-free with net cash of ₹883 crore, supporting future growth investments and shareholder returns (51% dividend payout ratio).